$UTHR News

United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says

RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price

The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease

Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation

Is United Therapeutics (UTHR) Undervalued After Its Legal Settlement?

United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement

What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.’

Liquidia Settles All United Therapeutics Litigation for $380.7 Million, Keeps Yutrepia on Market

Liquidia shares surge to 5-month high premarket on United Therapeutics settlement